The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Open accessAbstract
BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown. METHODS: , and no use of rescue therapy). The time to a renal-related event or death was assessed. RESULTS: A total of 448 patients underwent randomization (224 to the belimumab group and 224 to the placebo group). At week 104, significantly more patients in the belimumab group than in the placebo group had a primary efficacy renal response (43% vs. 32%; odds ratio, 1.6; 95% confidence interval [CI], 1.0 to 2.3; P = 0.03) and a complete renal response (30% vs. 20%; odds ratio, 1.7; 95% CI, 1.1 to 2.7; P = 0.02). The risk of a renal-related event or death was lower among patients who received belimumab than among those who received placebo (hazard ratio, 0.51; 95% CI, 0.34 to 0.77; P = 0.001). The safety profile of belimumab was consistent with that in previous trials. CONCLUSIONS: In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone. (Funded by GlaxoSmithKline; BLISS-LN ClinicalTrials.gov number, NCT01639339.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683
Self-citationHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationMycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Self-citationHoussiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,077
Self-citationBertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H. M., Boletis, J., Cervera, R., Dörner, T., Doria, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201940 · Cited by 1,007
Self-citationAnders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
The immune cell landscape in kidneys of patients with lupus nephritis
the Accelerating Medicines Partnership in SLE network, Arazi, A., Rao, D. A., Berthier, C. C., Davidson, A., Liu, Y., Hoover, P. J., Chicoine, A., Eisenhaure, T. M., Jonsson, A. H., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0398-x · Cited by 827
Self-citationThe frequency and outcome of lupus nephritis: results from an international inception cohort study
Hanly, J. G., O’Keeffe, A. G., Su, L., Urowitz, M. B., Romero-Diaz, J., Gordon, C., Bae, S.-C., Bernatsky, S., Clarke, A. E., Wallace, D. J., et al. (2016) · Rheumatology · doi:10.1093/rheumatology/kev311 · Cited by 647
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Dooley, M. A., Jayne, D., Ginzler, E. M., Isenberg, D., Olsen, N. J., Wofsy, D., Eitner, F., Appel, G. B., Contreras, G., Lisk, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014460 · Cited by 642
Self-citationTektonidou, M. G., Dasgupta, A., & Ward, M. M. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39594 · Cited by 582
Houssiau, F. A., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Petrovic, R., Fiehn, C., de Ramon Garrido, E., Gilboe, I.-M., Tektonidou, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.131995 · Cited by 499
Self-citationStohl, W., Hiepe, F., Latinis, K. M., Thomas, M., Scheinberg, M. A., Clarke, A., Aranow, C., Wellborne, F. R., Abud‐Mendoza, C., Hough, D. R., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34400 · Cited by 418
Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data
Austin, H. A., Boumpas, D. T., Vaughan, E. M., & Balow, J. E. (1994) · Kidney International · doi:10.1038/ki.1994.70 · Cited by 407
Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study
Furie, R., Nicholls, K., Cheng, T., Houssiau, F., Burgos‐Vargas, R., Chen, S., Hillson, J. L., Meadows‐Shropshire, S., Kinaszczuk, M., & Merrill, J. T. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38260 · Cited by 341
Self-citationDall'Era, M., Cisternas, M. G., Smilek, D. E., Straub, L., Houssiau, F. A., Cervera, R., Rovin, B. H., & Mackay, M. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39026 · Cited by 329
Self-citationSurvival analysis and causes of mortality in patients with lupus nephritis
Yap, D. Y. H., Tang, C. S. O., Ma, M. K. M., Lam, M. F., & Chan, T. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs073 · Cited by 319
Dooley, M., Houssiau, F., Aranow, C., D’Cruz, D., Askanase, A., Roth, D., Zhong, Z., Cooper, S., Freimuth, W., & Ginzler, E. (2013) · Lupus · doi:10.1177/0961203312465781 · Cited by 265
Self-citationTamirou, F., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Fiehn, C., Ayala Guttierez, M. D. M., Gilboe, I.-M., Tektonidou, M., Blockmans, D., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206897 · Cited by 216
Self-citationOutcomes in African Americans and Hispanics with lupus nephritis
Contreras, G., Lenz, O., Pardo, V., Borja, E., Cely, C., Iqbal, K., Nahar, N., de La Cuesta, C., Hurtado, A., Fornoni, A., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000243 · Cited by 202
Self-citationWofsy, D., Hillson, J., & Diamond, B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34624 · Cited by 165
Diagnosis and treatment of lupus nephritis flares—an update
Sprangers, B., Monahan, M., & Appel, G. B. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.220 · Cited by 134
Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy
Maria, N. I., & Davidson, A. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0401-9 · Cited by 128
Immunosuppressive treatment for proliferative lupus nephritis
Tunnicliffe, D. J., Palmer, S. C., Henderson, L., Masson, P., Craig, J. C., Tong, A., Singh‐Grewal, D., Flanc, R. S., Roberts, M. A., Webster, A. C., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002922.pub4 · Cited by 127
Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment
Touma, Z., Urowitz, M. B., Ibañez, D., & Gladman, D. D. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130005 · Cited by 104
Dall’Era, M., Stone, D., Levesque, V., Cisternas, M. G., & Wofsy, D. (2010) · Arthritis Care & Research · doi:10.1002/acr.20397 · Cited by 97
Kang, S., Fedoriw, Y. D., Brenneman, E. K., Truong, Y. K.-N., Kikly, K. K., & Vilen, B. J. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600281 · Cited by 87
Davidson, J. E., Fu, Q., Ji, B., Rao, S., Roth, D. A., Magder, L. S., & Petri, M. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.161554 · Cited by 76
Self-citationMarín‐Rosales, M., Cruz, Á., Salazar‐Camarena, D. C., Santillán‐López, E., Espinoza‐García, N., Muñóz-Valle, J. F., Ramírez‐Dueñas, M. G., Oregon‐Romero, E., Orozco‐Barocio, G., & Palafox‐Sánchez, C. A. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00549-8 · Cited by 52
Suso, J. P., Posso‐Osorio, I., Jiménez, C. A., Naranjo-Escobar, J., Ospina, F. E., Sánchez, A., Cañas, C. A., & Tobón, G. J. (2017) · Lupus · doi:10.1177/0961203317739132 · Cited by 35
Research works printed but not linked: 7
- 10.2174/1574887112666171123113200 · doi:10.2174/1574887112666171123113200
- 10.1155/2013/954292 · doi:10.1155/2013/954292
- 10.1177/0961203317717083 · doi:10.1177/0961203317717083
- 10.1136/lupus-2017-000213 · DOI
- 10.1186/s13075-015-0621-6 · DOI
- 10.1136/annrheumdis-2020-eular.2983 · doi:10.1136/annrheumdis-2020-eular.2983
- 10.1681/ASN.2006090992 · doi:10.1681/asn.2006090992
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationEULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S.-C., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224762 · Cited by 1,081
Self-citationUpdate οn the diagnosis and management of systemic lupus erythematosus
Fanouriakis, A., Tziolos, N., Bertsias, G., & Boumpas, D. T. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218272 · Cited by 753
Rovin, B. H., Teng, Y. K. O., Ginzler, E. M., Arriens, C., Caster, D. J., Romero-Diaz, J., Gibson, K., Kaplan, J., Lisk, L., Navarra, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00578-x · Cited by 635
Self-citationSystemic Lupus Erythematosus: A Review
Siegel, C. H., & Sammaritano, L. R. (2024) · JAMA · doi:10.1001/jama.2024.2315 · Cited by 535
Metadata
- Authors
- Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., Saxena, A., Green, Y., Ji, B., Kleoudis, C., Burriss, S. W., Barnett, C., & Roth, D. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-09-17
- Volume
- 383
- Issue
- 12
- Pages
- 1117-1128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3085025551
- Cited by
- 1,032
- References
- 33
- FWCI
- 81.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- GSK (GSK Study 114054)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.